Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

BACKGROUND: Due to waning immunity and protection against infection with SARS-CoV-2, a third dose of a homologous or heterologous COVID-19 vaccine has been proposed by health agencies for individuals who were previously primed with two doses of an inactivated COVID-19 vaccine. METHODS: We did a rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing-Xin, Wu, Shi-Po, Guo, Xi-Ling, Tang, Rong, Huang, Bao-Ying, Chen, Xiao-Qin, Chen, Yin, Hou, Li-Hua, Liu, Jing-Xian, Zhong, Jin, Pan, Hong-Xing, Shi, Feng-Juan, Xu, Xiao-Yu, Li, Zhuo-Pei, Zhang, Xiao-Yin, Cui, Lun-Biao, Tan, Wen-Jie, Chen, Wei, Zhu, Feng-Cai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122540/
https://www.ncbi.nlm.nih.gov/pubmed/35605625
http://dx.doi.org/10.1016/S2213-2600(22)00087-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122540/
https://www.ncbi.nlm.nih.gov/pubmed/35605625
http://dx.doi.org/10.1016/S2213-2600(22)00087-X

Ejemplares similares